Those in the stock know that chances of Adalta achieving milestones are good.
Most have researched it over the last 2 years and during that time the strategy has become much more robust from management.
Fibrosis is a big market.
Quality biotech's rerate heavily
NOX - 13 cents to $1.85
PAR
PNV
OCC
BOT
1AD is in that league somewhere.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.225M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $1.65K | 825.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 12245025 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 17797718 | 21 |
View Market Depth
| Last trade - 10.24am 28/07/2025 (20 minute delay) ? |
| 1AD (ASX) Chart |